Mabion, a fully integrated CDMO located in central Europe, was established in 2007 to develop and support the development of protein-based biotherapeutics, including monoclonal antibodies, vaccine antigens and other large proteins. With 17 years of experience, Mabion offers an ‘end-to-end solution, covering all stages of biologic drug development: from early clone selection and small-scale manufacturing through process scale-up, bioanalytical testing, large-scale manufacturing to sterile fill-finish, packaging and serialization. With broad capabilities and well-qualified, experienced staff, Mabion is a perfect long-term partner for any project involving therapeutic proteins, whether your product is in pre-clinical or clinical development or already commercially available. | Mabion is a fully integrated CDMO offering a wide services associated with the development and GMP manufacturing of biotherapeutics, including monoclonal antibodies and any recombinant protein-based products. We offers an end-to-end solution, covering all stages of biologic drug development from CLD through process scale-up and analytics to sterile fill-finish and QC release. Mabion is of the most suitable solution for customers who have recombinant protein-based products in their portfolio, manufactured using mammalian cell line culture technology. Our facilities located in central Poland, which operate in full compliance with GMP, GLP, GCP and ISO principles, can run small- and large-scale manufacturing of biotherapeutics, providing the customers with high-quality products at optimal efficiency and competitive pricing.
MabPlex USA
MabPlex provides complete contract development and manufacturing services for CHO-based biologics and antibody-drug conjugates. From cell-line development and linker-payload synthesis to commercial drug product and packaging, we can consolidate your program under a single experienced provider. With over 1 million square feet of manufacturing space and a global management presence, we strive to deliver a high-quality, comprehensive solution for your bioprocess development and manufacturing needs.
LUPIN Biotech
LUPIN Inc. (LUPIN Biotech’s parent) is a $2.5B global Generic Pharma and BioSimilars company meeting the needs of patients around the World! Given our ongoing success, LUPIN Biotech now partners with biopharma developers as a preferred-choice provider of CDMO services to develop and produce their biotherapeutic assets (ADCs, mAbs, bsAbs, fusion proteins, etc.) through to IND and beyond (BLA/MAA and commercial launch). LUPIN’s capabilities include CLD, analytical and formulation development, process optimization, scale-up, clinical and commercial DS/DP manufacturing, pre-clinical tox. studies, Phase I Safety Trials, as well as associated regulatory support. LUPIN provides biotherapeutic developers in-search of a qualified CDMO the following key advantages: I. Global, cGMP [mammalian] production capabilities at up to and including multiple 2000L scale using SUBs for a total of 15,000L capacity…already reviewed by major regulatory authorities around the world (EMA, PMDA, etc.) II. An expert team, experienced at successfully progressing our own biotherapeutics (e.g. our Enbrel biosimilar) through to approval in Europe, Japan, Canada and soon in the US III. An approved Quality System, routinely vetted by international regulatory agencies responsible for global product review and approval…Quality is ‘built-in’ by design, as part of the process IV. Reduced costs commensurate with an India-based labor force and associated low overhead affording ‘best-in-class pricing’ Most importantly, our location and affordable pricing enable us to offer clients considerable flexibility (e.g. customized payment terms), while delivering within budget and on-time.
LTS Lohmann Therapy Systems
LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (TTS) and Oral Thin Films (OTF) for the pharmaceutical industry. LTS is also advancing emerging drug delivery technologies like Micro Array Patches (MAP) for the transdermal delivery of large molecules, biological actives and vaccines. LTS´s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. Founded in 1984, LTS operates today from three sites: Andernach, Germany, West Caldwell, NJ, USA and St. Paul, MN, USA. LTS has also a representative office in Shanghai, China. | We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its Sorrel(TM) wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China. | LTS is a trusted technology partner for the pharmaceutical industry. We develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). We are also advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.
LOTTE BIOLOGICS
LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb’s Syracuse manufacturing site. Furthermore, with a plan for Mega Plants in Korea with a total capacity exceeding 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse site is 35,000L (5,000L x7), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse site has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market. The Mega Plants in South Korea, with a total capacity exceeding 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Mega Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en | LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb’s Syracuse manufacturing site. Furthermore, with a plan for Songdo Bio Campus in Korea with a total capacity up to 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse Bio Campus is 40,000L (5,000L x8), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse Bio Campus has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market, which is projected to be fully in operation by Q1 2025. The Songdo Bio Campus in South Korea, with a total capacity up to 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Songdo Bio Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en | LOTTE BIOLOGICS was established in 2022 and is headquartered in Seoul, South Korea. Utilizing a two-track strategy of acquiring and building, LOTTE BIOLOGICS is solidifying its competitiveness in the CDMO market. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received over 62 regulatory approvals from agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 3,000L bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a top-tier global CDMO company in the biopharmaceutical industry.
Lifecore Biomedical
Lifecore Biomedical is a fully integrated CDMO offering expertise in specialty formulation, aseptic filling, and final packaging of both complex medical devices and injectable pharmaceuticals. We currently manufacture FDA-approved commercial products at our three cGMP facilities and have received numerous certifications from regulators in Europe, Japan, and Brazil as well as the International Organization for Standardization (ISO). Lifecore has also been a leading manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) since 1981 when we developed our proprietary, fermentation-based HA process. Since then, we have become the preferred viscoelastic supplier to ophthalmic market leaders and our products have been used in the treatment of more than 150 million patients worldwide. For decades, Lifecore’s commitment to customers has enabled our success and allowed us to expand our infrastructure, increasing capacity to help support growing demands from the global pharmaceutical market. | More than a CDMO, your discovery deserves a HOME. Lifecore Biomedical is a fully integrated CDMO with differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products. Proven capabilities with complex formulations and highly viscous products (>100,000 cP) highlight our ability to undertake challenges. With 20+ commercial products and a 40+ year regulatory track record, we are deeply knowledgeable on how to efficiently drive programs from clinical to commercial. No matter the size of your organization or the stage of your project, let’s explore how Lifecore may be the right HOME for your molecule. Process Development and Fill/Finish Services • Development, fill and finish of sterile injectables. • Syringes, vials, and cartridges, including proprietary sterile filtration system. • Expertise in highly viscous and complex formulations. • Pre-clinical through commercial support for virtual organizations to large pharma. • QMS supports API & Excipient, Medical Devices, Drug & Combination Products, Biologics. Additional Services • Extensive on-site biological, analytical, and physical testing with redundant labs. • ICH stability studies. • Range of packaging, handling, serialization and sterilization options. Sodium Hyaluronate • Research-grade, pharmaceutical-grade, hydrogels, and custom modifications. • Broad range of average molecular weights. • U.S. DMF (FDA for drug and device) approved, EP-certified, and JP-compliant.
Life Science Oklahoma
Life Science Oklahoma (LSOK) supports, advances, and promotes the growth and expansion of Oklahoma’s Life Science Industry. We facilitate a collaborative and supportive ecosystem that connects and assists industry stakeholders to advance innovation, economic development, and health outcomes in Oklahoma. LSOK unites stakeholders to create a robust environment for industry growth and to enhance the competitiveness and sustainability of Oklahoma’s life science sector on a national and global scale.
Laboratorios Richmond SACIF
Richmond CDMO fully-integrated biotech services from development to supply chain. Single-use upstream and downstream GMP processing Mammalian cell culture platform for recombinant proteins and adenoviruses Fully automated filling and packaging lines for vials, pfs and cartridges. | We are a regional pharmaceutical company and CDMO based in Argentina that develops and produces medicines using cutting-edge technology. Our portfolio includes generic products, biosimilars, and technology licenses and transfers from key countries. We also create innovative solutions by combining different active ingredients in a single tablet and developing user-friendly packaging that facilitates therapeutic adherence and significantly improves our patients’ quality of life. Biotechnology Plant: A unit dedicated to the production of 100% of the production cycle for both vaccines and complex biotechnological products. As CDMO we offer our development and production capacity for biologicals, including vaccines and biosimilars. The plant has over 10,000 m2 dedicated to the production of biological active ingredients and finished products, it includes a GMP-compliant pilot plant and QC laboratories. The plant is equipped with single-use technology (upto 1000-L bioprocess) and has completely independent F&F areas distributed across two lines, providing maximum flexibility. The total estimated capacity will be approximately 80 million vials and 28 million syringes per year.
LABORATORIOS CASASCO
Laboratorios Casasco is a pharmaceutical manufacturing company headquartered in Buenos Aires, Argentina. It was founded in 1876, making it one of the country’s oldest pharmaceutical companies. Our mission is to advance global health and well-being by developing pharmaceutical products of the highest quality, grounded in scientific excellence and ethical integrity. Our portfolio includes cardiovascular health, Urology, Neurology and psychiatry, Immunology, Endocrinology (e.g., diabetes), Anti-infectives, Gastrointestinal treatments, Women’s health, and preventive medicine. Born in the 19th century, walked along the 20th century, and entered the 21st century as an enduring Argentine endeavor through the centuries.
Laboratorio Elea
Elea Phoenix is a top Argentinean Laboratory that has been researching and developing trustworthy and innovative medicines for a wide range of medical specialities since 1939. With leading trademarks, research and development projects of our own and licences from International renowed Companies. With Industrial Manufacturing Plants that operate efficiently, a wide distribution network, we focus firmly on the development of new products, in the following areas: Oncology, Biotechnology, Cardiology, Neuropsychiatry, Woman`s Health. Laboratorio ELEA is currently working with monoclonal antibodies, recombinant proteins, synthetic peptides, therapeutic vaccines for oncology. We are the first Company to launch a monoclonal antibody in 1997 , and in 2014 we launched the first Biosimilar mAb for Rituximab and Bevacizumab in 2016 . Now with have a potfolio of over 600 products, ranking 2nd for OTC/RX products. We have a strong portfolio in Biotech, launching Biopharmaceutical products every 2 years. | Elea is a top Argentinean Laboratory that has been researching and developing trustworthy and innovative medicines for a wide range of medical specialities since 1939. With leading trademarks, research and development projects of our own and licences from International renowed Companies. With Industrial Manufacturing Plants in Argentina and Latam that operate efficiently, a wide distribution network in several countries, we focus firmly on the development of new products, in the following areas: Oncology, Biotechnology, Cardiology, Neuropsychiatry, Woman`s Health. Laboratorio ELEA is currently working with monoclonal antibodies, recombinant proteins, synthetic peptides, therapeutic vaccines for oncology. We are the first Company to launch a monoclonal antibody in 1997 , and in 2014 we launched the first Biosimilar mAb for Rituximab and Bevacizumab in 2016 . Now with have a potfolio of over 600 products, ranking 2nd for OTC/RX products. We have a strong portfolio in Biotech, launching Biopharmaceutical products every 2 years. | We are an Argentine pharmaceutical company with more than 80 years of experience, dedicated to the research, development, and manufacturing of quality medicines for various medical specialties. Since 1939, we have stood out for offering innovative solutions that improve the health and quality of life of people, both in Argentina and throughout Latin America. ✅ We integrate our own research and development, alliances with important international laboratories and high-tech production plants, ensuring that innovation is present in every stage of our process. All this, together with an extensive distribution network, positions us among the leaders in the Argentine pharmaceutical market. Our main therapeutic areas are: Women’s Health – Urology – Anti-infectives – Respiratory – Internal Medicine – Ophthalmology – Neurosciences – Cardiometabolism – Osteoarticular – Gastroenterology – Oncology and Biotechnology – HIV – Over-the-Counter. We have a strong portfolio of Biopharmaceutical products in the market (EPO, Rituximab, Bevacizumab, Trastuzumab, Adalimumab, Pembrolizumab, Racotumomab, Nimotuzumab).